Paratek Pharmaceuticals Inc
F:N4CN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Paratek Pharmaceuticals Inc
Other Liabilities
Paratek Pharmaceuticals Inc
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Paratek Pharmaceuticals Inc
F:N4CN
|
Other Liabilities
$50.3m
|
CAGR 3-Years
114%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Liabilities
$17.3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Liabilities
$5B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
6%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Liabilities
$20.4B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Liabilities
$7.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
0%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Liabilities
$9.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
0%
|
CAGR 10-Years
8%
|
|
Paratek Pharmaceuticals Inc
Glance View
Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. The company is headquartered in Boston, Massachusetts and currently employs 207 full-time employees. The company went IPO on 2006-05-10. The firm is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The firm's lead product, NUZYRA (omadacycline), is an oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI), caused by susceptible pathogens. Omadacycline is used in the emergency room, hospital, and community care settings. Its second product, SEYSARA (Sarecycline), is an oral therapy for the treatment of moderate to severe acne vulgaris.
See Also
What is Paratek Pharmaceuticals Inc's Other Liabilities?
Other Liabilities
50.3m
USD
Based on the financial report for Jun 30, 2023, Paratek Pharmaceuticals Inc's Other Liabilities amounts to 50.3m USD.
What is Paratek Pharmaceuticals Inc's Other Liabilities growth rate?
Other Liabilities CAGR 5Y
55%
Over the last year, the Other Liabilities growth was 95%. The average annual Other Liabilities growth rates for Paratek Pharmaceuticals Inc have been 114% over the past three years , 55% over the past five years .
